To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

NCT03277209 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped terminated due to slow accrual

Conditions

Pancreas Cancer

Interventions

DRUG: Plerixafor

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]